A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants
Launched by BRISTOL-MYERS SQUIBB · Nov 30, 2022
Trial Information
Current as of November 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must be Chinese (both biological parents are ethnically Chinese).
- • Body mass index (BMI) of 18.0 through 28.0 kilograms/meter squared (kg/m\^2), inclusive. BMI = weight (kg)/\[height (m)\]\^2.
- • Body weight ≥ 50.0 kg.
- Exclusion Criteria:
- • History of clinically significant infection within 4 weeks of dosing on Day 1.
- • Significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
- • Condition(s) which may confound the ability to interpret data from the study, as determined by the investigator.
- • Other protocol-defined inclusion/exclusion criteria apply.
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials